Claims for Patent: 6,686,382

Summary for Patent: 6,686,382

Title:	Sulfonamides and derivatives thereof that modulate the activity of endothelin
Abstract:	Thienyl-, furyl-, pyrrolyl- and phenylsulfonamides, formulations of pharmaceutically-acceptable derivatives thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides, N-(isoxazolyl)pyrrolylsulfonamides and N-(isoxazolyl)phenylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or pharmaceutically acceptable derivatives thereof that inhibit the activity of endothelin are also provided.
Inventor(s):	Wu; Chengde (Pearland, TX), Blok; Natalie (Houston, TX), Holland; George W. (North Caldwell, NJ)
Assignee:	Encysive Pharmaceuticals Inc. (Bellaire, TX)
Application Number:	09/751,825
Patent Claims:	1. A compound that has formula IV: ##STR45## or pharmaceutically acceptable derivatives thereof, wherein: X is S or --C(R.sup.3).dbd.(C(R.sup.4)--; R.sup.1 is lower alkyl; R.sup.2 is lower alkyl; R.sup.3 and R.sup.4 are independently selected from among hydrogen, halo, cyano, cyanoalkyl, C(O)R.sup.41, alkyl, alkenyl, cycloalkyl and aryl, or together form alkylene or alkenylene, where R.sup.41 is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, alkylamino, dialkylamino, arylamino, diarylamino, alkylsulfonylamino, arylsulfonylamino, alkylsulfonylalkylamino, alkylsulfonylarylamino, arylsulfonylalkylamino or arylsulfonylarylamino; R.sup.5 is lower alkyl or --(CH.sub.2).sub.x C(O)(CH.sub.2).sub.y CH.sub.3 ; R.sup.6 is lower alkyl, --(CH.sub.2).sub.x C(O)(CH.sub.2).sub.y CH.sub.3, or heteroaryl; R.sup.7 is hydrogen, hydroxy, alkoxy, lower alkyl, S(O).sub.2 NHR.sup.50 or OS(O).sub.2 NR.sup.38 R.sup.39 ; R.sup.38 and R.sup.39 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, haloalkyl, alkylaryl, heterocyclyl, arylalkyl, arylalkoxy, alkoxy, aryloxy, cycloalkyl, cycloalkenyl and cycloalkynyl; x and y are each independently 0 to 14; R.sup.50 is hydrogen, lower alkyl, lower alkoxy or heteroaryl; Y and R.sup.8 are selected from (i) or (ii) as follows: (i) Y is O; and R.sup.8 is CONR.sup.38 R.sup.39, CN, heteroaryl, alkylsulfonyl, halide, pseudohalide, hydroxyalkyl, C(O)(CH.sub.2).sub.x S(O).sub.2 (CH.sub.2).sub.y CH.sub.3 or C(.dbd.N--OR.sup.38)(CH.sub.2).sub.y CH.sub.3 ; or (ii) Y and R.sup.8 together with the atoms to which they are attached, form a 3 to 16 membered unsubstituted or substituted cyclic or heterocyclic ring; R.sup.9 is H; Y.sup.1 and Y.sup.2 are each independently carbon; a is 1; b is 1; and W is NH. 2. The compound of claim 1, wherein: X is S; R.sup.3 and R.sup.4 are each H; Y.sup.1 and Y.sup.2 are each carbon; and a and b are each 1. 3. The compound of claim 1, wherein the compound has formula V: ##STR46## and pharmaceutically acceptable derivatives thereof, wherein: X is S or --CH.dbd.CH--; R.sup.1 is lower alkyl; R.sup.2 is lower alkyl; R.sup.3 and R.sup.4 are each hydrogen; R.sup.5 is lower alkyl or --(CH.sub.2).sub.x C(O)(CH.sub.2).sub.y CH.sub.3 ; R.sup.6 is lower alkyl, --(CH.sub.2).sub.x C(O)(CH.sub.2).sub.y CH.sub.3, or heteroaryl; R.sup.7 is selected from the group consisting of hydrogen, hydroxy, alkoxy, lower alkyl, S(O).sub.2 NHR.sup.50 and OS(O).sub.2 NR.sup.38 R.sup.39 ; R.sup.38 and R.sup.39 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, haloalkyl, alkylaryl, heterocyclyl, arylalkyl, arylalkoxy, alkoxy, aryloxy, cycloalkyl, cycloalkenyl and cycloalkynyl; x and y are each independently 0 to 14; R.sup.50 is hydrogen, lower alkyl, lower alkoxy or heteroaryl; Y and R.sup.8 are selected from (i) or (ii) as follows: (i) Y is O; and R.sup.8 is CONR.sup.38 R.sup.39, CN, heteroaryl, alkylsulfonyl, halide, pseudohalide, hydroxyalkyl, C(O)(CH.sub.2).sub.x S(O).sub.2 (CH.sub.2).sub.y CH.sub.3 or C(.dbd.N--OR.sup.38)(CH.sub.2).sub.y CH.sub.3 ; or (ii) Y and R.sup.8 together with the atoms to which they are attached, form a 3 to 16 membered unsubstituted or substituted cyclic or heterocyclic ring; R.sup.9 is H; Y.sup.1 and Y.sup.2 are each independently carbon; a is 1; b is 1; and W is NH. 4. The compound of claim 3, wherein R.sup.1 is Me; and R.sup.2 is Me. 5. The compound of claim 3, wherein: R.sup.5 is Me or acetyl; R.sup.6 is Me, acetyl or 2-oxazolyl; R.sup.7 is H, Me, OSO.sub.2 NMe.sub.2, OCH.sub.2 -cyclopropyl, hydroxy or SO.sub.2 NH-(4-chloro-3-methyl-5-isoxazolyl); Y and R.sup.8 are selected from (i) or (ii), as follows: (i) Y is O; and R.sup.8 is C(O)CH.sub.2 SO.sub.2 CH.sub.3, CN, C(O)N(Me)(CH.sub.2 -t-Bu), SO.sub.2 Me, 2-oxazolyl, SO.sub.2 -isopropyl, SO.sub.2 -n-propyl, CH(OH)Me, C(O)NMe.sub.2, C(.dbd.N--OMe)Me, C(O)Et or Cl; or (ii) Y and R.sup.8 together form --CO--N.dbd. or --CO--C(CN).dbd.; R.sup.9 is H; Y.sup.1 and Y.sup.2 are each independently carbon; a is 1; b is 1; and W is NH. 6. The compound of claim 3, wherein: X is S; R.sup.1 is Me; R.sup.2 is Me; R.sup.3, R.sup.4 and R.sup.9 are H; Y is O; W is NH; and Y.sup.1 and Y.sup.2 are each carbon. 7. The compound of claim 6, wherein the compound has the formula VI: ##STR47## or pharmaceutically acceptable derivatives thereof, wherein: R.sup.1 is Me; R.sup.5 is Me or acetyl; R.sup.6 is Me, acetyl or 2-oxazolyl; R.sup.7 is H, Me, OSO.sub.2 NMe.sub.2, OCH.sub.2 -cyclopropyl, hydroxy or SO.sub.2 NH-(4-chloro-3-methyl-5-isoxazolyl); and R.sup.8 is C(O)CH.sub.2 SO.sub.2 CH.sub.3, CN, C(O)N(Me)(CH.sub.2 -t-Bu), SO.sub.2 Me, 2-oxazolyl, SO.sub.2 -isopropyl, SO.sub.2 -n-propyl, CH(OH)Me, C(O)NMe.sub.2, C(.dbd.N--OMe)Me, C(O)Et or Cl. 8. The compound of claim 7, wherein R.sup.1, R.sup.5 and R.sup.6 are Me; and R.sup.7 is hydrogen. 9. The compound of claim 1 that is N-(2-cyano-3,4,6-trimethylphenyl)-3-{[(3,4-dimethyl-5-isoxazolyl)amino]sul fonyl}-2-thiophenecarboxamide or pharmaceutically acceptable derivatives thereof. 10. The compound of claim 1, wherein X is --C(R.sup.3).dbd.C(R.sup.4)--. 11. A compound that has formula VII: ##STR48## and pharmaceutically acceptable derivatives thereof, where R.sup.1 and R.sup.2 are either (i), (ii) or (iii) as follows: (i) R.sup.1 and R.sup.2 are each independently selected from H, NH.sub.2, NO.sub.2, halide, pseudohalide, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkoxy, alkylamino, alkylthio, haloalkyl, alkylsulfinyl, alkylsulfonyl, aryloxy, arylamino, arylthio, arylsulfinyl, arylsulfonyl, haloaryl, alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, arylcarbonyl, formyl, substituted or unsubstituted amido, and substituted or unsubstituted ureido, in which the alkyl, alkenyl and alkynyl portions contain from 1 up to about 14 carbon atoms and are either straight or branched chains or cyclic, and the aryl portions contain from about 4 to about 16 carbons, except that R.sup.2 is not halide or pseudohalide; or, (ii) R.sup.1 and R.sup.2 together form --(CH.sub.2).sub.n --, where n is 3 to 6; or, (iii) R.sup.1 and R.sup.2 together form 1,3-butadienyl (--CH.dbd.CH--CH.dbd.CH--); W is O, NH or (CH.sub.2).sub.z wherein z is 0 to 6; and Y is O, S, or, together with R.sup.8 and the atoms to which they are attached, form a 3 to 16 membered unsubstituted or substituted cyclic or heterocyclic ring; R.sup.3 and R.sup.4 are independently selected from among hydrogen, halo, cyano, cyanoalkyl, C(O)R.sup.41, alkyl, alkenyl, cycloalkyl and aryl, or together form alkylene or alkenylene, where R.sup.41 is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, alkylamino, dialkylamino, arylamino, diarylamino, alkylsulfonylamino, arylsulfonylamino, alkylsulfonylalkylamino, alkylsulfonylarylamino, arylsulfonylalkylamino or arylsulfonylarylamino; Y.sup.1 and Y.sup.2 are each independently carbon; a and b are each independently 1; R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are each independently selected from (i) or (ii) as follows: (i) R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are each independently selected from among H, NHR.sup.38, CONR.sup.38 R.sup.39, NO.sub.2, cyano, halide, pseudohalide, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkoxy, alkylamino, alkylthio, haloalkyl, alkylsulfinyl, alkylsulfonyl, alkoxycarbonyl, alkylcarbonyl, alkenylthio, alkenylamino, alkenyloxy, alkenylsulfinyl, alkenylsulfonyl, arylaminocarbonyl, alkylaminocarbonyl, aminocarbonyl, (alkyl-aminocarbonyl)alkyl, acetoxy, hydroxyl, carboxyl, carboxyalkyl, carboxyalkenyl, alkylsulfonylaminoalkyl, cyanoalkyl, acetyl, acetoxyalkyl, hydroxyalkyl, alkoxyalkoxy, (acetoxy)alkoxy, (hydroxy)alkoxy, formyl, sulfonyl chlorides, amino acids, hexoses, O-glycosides, riboses, --(CH.sub.2).sub.x C(O)(CH.sub.2).sub.y CH.sub.3, --(CH.sub.2).sub.x CH.sub.3, (CH.sub.2).sub.x NH-lower alkyl, --(CH.sub.2).sub.1 to 14 C(O)NH.sub.2, a primary or secondary amide, --(CH.sub.2).sub.x COOH, --(CH.sub.2).sub.x CH(COOH)(CH.sub.2).sub.y CH.sub.3, C(O)(CH.sub.2).sub.x S(O).sub.2 (CH.sub.2).sub.y CH.sub.3, C(.dbd.N--OR.sup.38)(CH.sub.2).sub.y CH.sub.3, --C(O)C(O)(CH.sub.2).sub.y CH.sub.3, --(CH.sub.2).sub.x N(CH.sub.3).sub.2, S(O).sub.2 NHR.sup.50, OS(O).sub.2 NR.sup.38 R.sup.39, alkylaryl, alkylheteroaryl, --C(O)NH-heteroaryl and --C(O)N(H)N(H)R.sup.50 ; R.sup.38 and R.sup.39 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, haloalkyl, alkylaryl, heterocyclyl, arylalkyl, arylalkoxy, alkoxy, aryloxy, cycloalkyl, cycloalkenyl and cycloalkynyl; x and y are each independently 0 to 14; R.sup.50 is a substituent such as hydrogen, lower alkyl, lower alkoxy or heteroaryl; or (ii) at least two of R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9, which substitute adjacent carbons on the ring, together form alkylenedioxy, alkylenethioxyoxy or alkylenedithioxy which is unsubstituted or substituted by replacing one or more hydrogens with halide, lower alkyl, lower alkoxy or halo lower alkyl, and the others of R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are selected as in (i). 12. The compound of claim 11, wherein R.sup.3, R.sup.4 and R.sup.9 are H; Y is O; and W is NH. 13. The compound of claim 11, wherein R.sup.1 and R.sup.2 are each selected independently from among alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, halide, pseudohalide or H, except that R.sup.2 is not halide. 14. The compound of claim 11, wherein R.sup.1 is lower alkyl or halide; and R.sup.2 is lower alkyl. 15. The compound of claim 11, wherein the compound has formula VIII: ##STR49## or pharmaceutically acceptable derivatives thereof, wherein: R.sup.1 is lower alkyl or halide; R.sup.5 is lower alkyl or --(CH.sub.2).sub.x C(O)(CH.sub.2).sub.y CH.sub.3 ; R.sup.6 is lower alkyl, --(CH.sub.2).sub.x C(O)(CH.sub.2).sub.y CH.sub.3, or heteroaryl; R.sup.7 is hydrogen, hydroxy, alkoxy, lower alkyl, S(O).sub.2 NHR.sup.50 or OS(O).sub.2 NR.sup.38 R.sup.39 ; and R.sup.8 is CONR.sup.38 R.sup.39, CN, heteroaryl, alkylsulfonyl, (CH.sub.2).sub.x C(O)(CH.sub.2).sub.y CH.sub.3, alkyl, halide, pseudohalide, hydroxyalkyl, C(O)(CH.sub.2).sub.x S(O).sub.2 (CH.sub.2).sub.y CH.sub.3 or C(.dbd.N--OR.sup.38)(CH.sub.2).sub.y CH.sub.3. 16. The compound of claim 15, wherein: R.sup.5 is Me or acetyl; R.sup.6 is Me, acetyl or 2-oxazolyl; R.sup.7 is H, Me, OSO.sub.2 NMe.sub.2, OCH.sub.2 -cyclopropyl, hydroxy or SO.sub.2 NH-(4-chloro-3-methyl-5-isoxazolyl); and R.sup.8 is C(O)CH.sub.2 SO.sub.2 CH.sub.3, C(O)Me, CN, C(O)N(Me)(CH.sub.2 -t-Bu), SO.sub.2 Me, 2-oxazolyl , SO.sub.2 -isopropyl, SO.sub.2 -n-propyl, CH(OH)Me, C(O)NMe.sub.2, C(.dbd.N--OMe)Me, Me, C(O)Et, Cl, n-propyl or ethyl. 17. The compound of claim 15, wherein R.sup.5 and R.sup.6 are Me; R.sup.7 is H; and R.sup.8 is C(O)Me. 18. The compound of claim 15 that is N-(4-chloro-3-methyl-5-isoxazolyl)-2-(2acetyl-4,6-dimethylphenylaminocarbo nyl)benzenesulfonamide. 19. A compound that has formula X: ##STR50## or pharmaceutically acceptable derivatives thereof, where R.sup.1 and R.sup.2 are either (i), (ii) or (iii) as follows: (i) R.sup.1 and R.sup.2 are each independently selected from H, NH.sub.2, NO.sub.2, halide, pseudohalide, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkoxy, alkylamino, alkylthio, haloalkyl, alkylsulfinyl, alkylsulfonyl, aryloxy, arylamino, arylthio, arylsulfinyl, arylsulfonyl, haloaryl, alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, arylcarbonyl, formyl, substituted or unsubstituted amido, and substituted or unsubstituted ureido, in which the alkyl, alkenyl and alkynyl portions contain from 1 up to about 14 carbon atoms and are either straight or branched chains or cyclic, and the aryl portions contain from about 4 to about 16 carbons, except that R.sup.2 is not halide or pseudohalide; or, (ii) R.sup.1 and R.sup.2 together form --(CH.sub.2).sub.n --, where n is 3 to 6; or, (iii) R.sup.1 and R.sup.2 together form 1,3-butadienyl (--CH.dbd.CH--CH.dbd.CH--); Y.sup.1 and Y.sup.2 are each independently carbon or nitrogen; a and b are each independently 0 or 1; R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are each independently selected from (i) or (ii) as follows: (i) R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are each independently selected from among H, NHR.sup.38, CONR.sup.38 R.sup.39, NO.sub.2, cyano, halide, pseudohalide, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkoxy, alkylamino, alkylthio, haloalkyl, alkylsulfinyl, alkylsulfonyl, alkoxycarbonyl, alkylcarbonyl, alkenylthio, alkenylamino, alkenyloxy, alkenylsulfinyl, alkenylsulfonyl, arylaminocarbonyl, alkylaminocarbonyl, aminocarbonyl, (alkyl-aminocarbonyl)alkyl, acetoxy, hydroxyl, carboxyl, carboxyalkyl, carboxyalkenyl, alkylsulfonylaminoalkyl, cyanoalkyl, acetyl, acetoxyalkyl, hydroxyalkyl, alkoxyalkoxy, (acetoxy)alkoxy, (hydroxy)alkoxy, formyl, sulfonyl chlorides, amino acids, hexoses, O-glycosides, riboses, --(CH.sub.2).sub.x C(O)(CH.sub.2).sub.y CH.sub.3, --(CH.sub.2).sub.x CH.sub.3, (CH.sub.2).sub.x NH-lower alkyl, --(CH.sub.2).sub.1 to 14 C(O)NH.sub.2, a primary or secondary amide, --(CH.sub.2).sub.x COOH, --(CH.sub.2).sub.x CH(COOH)(CH.sub.2).sub.y CH.sub.3, C(O)(CH.sub.2).sub.x S(O).sub.2 (CH.sub.2).sub.y CH.sub.3, C(.dbd.N--OR.sup.38)(CH.sub.2).sub.y CH.sub.3, --C(O)C(O)(CH.sub.2).sub.y CH.sub.3, --(CH.sub.2).sub.x N(CH.sub.3).sub.2, S(O).sub.2 NHR.sup.50, OS(O).sub.2 NR.sup.38 R.sup.39, alkylaryl, alkylheteroaryl, --C(O)NH-heteroaryl and --C(O)N(H)N(H)R.sup.50 ; R.sup.38 and R.sup.39 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, haloalkyl, alkylaryl, heterocyclyl, arylalkyl, arylalkoxy, alkoxy, aryloxy, cycloalkyl, cycloalkenyl and cycloalkynyl; x and y are each independently 0 to 14; R.sup.50 is a substituent such as hydrogen, lower alkyl, lower alkoxy or heteroaryl; or (ii) at least two of R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9, which substitute adjacent carbons on the ring, together form alkylenedioxy, alkylenethioxyoxy or alkylenedithioxy which is unsubstituted or substituted by replacing one or more hydrogens with halide, lower alkyl, lower alkoxy or halo lower alkyl, and the others of R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are selected as in (i). 20. The compound of claim 19, wherein: R.sup.1 is halo or lower alkyl; R.sup.2 is lower alkyl; R.sup.5 is lower alkyl or --(CH.sub.2).sub.x C(O)(CH.sub.2).sub.y CH.sub.3 ; R.sup.6 is lower alkyl --(CH.sub.2).sub.x C(O)(CH.sub.2).sub.y CH.sub.3, or heteroaryl; R.sup.7 is hydrogen, hydroxy, alkoxy, lower alkyl, S(O).sub.2 NHR.sup.50 and OS(O).sub.2 NR.sup.38 R.sup.39 ; where R.sup.38 and R.sup.39 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, haloalkyl, alkylaryl, heterocyclyl, arylalkyl, arylalkoxy, alkoxy, aryloxy, cycloalkyl, cycloalkenyl and cycloalkynyl; x and y are each independently 0 to 14; and R.sup.50 is hydrogen, lower alkyl, lower alkoxy or heteroaryl; R.sup.8 is CONR.sup.38 R.sup.39, CN, heteroaryl, alkylsultonyl, (CH.sub.2).sub.x C(O)(CH.sub.2).sub.y CH.sub.3, alkyl, halide, pseudohalide, hydroxyalkyl, C(O)(CH.sub.2).sub.x S(O).sub.2 (CH.sub.2).sub.y CH.sub.3 or C(.dbd.N--OR.sup.38)(CH.sub.2).sub.y CH.sub.3 ; R.sup.9 is H; Y.sup.1 and Y.sup.2 are each independently carbon; a is 1; and b is 1. 21. The compound of claim 20, wherein Y.sup.1 and Y.sup.2 are carbon; a and b are each 1; R.sup.5, R.sup.6, and R.sup.8 are lower alkyl; and R.sup.7 is H or SO.sub.2 NHR.sup.50, where R.sup.50 is heteroaryl. 22. The compound of claim 19 selected from the group consisting of N-(4-chloro-3-methyl-5-isoxazolyl)-2(2,4,6-trimethylbenzyl)benzo[b]thiophe ne-3-sulfonamide and N-(4-chloro-3-methyl-5-isoxazolyl)-2-(3-(4-chloro-3-methyl-5-isoxazolyl)am inosulfonyl-2,4,6-trimethylbenzyl)benzo[b]thiophene-3-sulfonamide. 23. A pharmaceutically acceptable salt of the compound of claim 1. 24. The salt of claim 23 that is a sodium salt. 25. A pharmaceutical composition, comprising and effective amount of a compound of claim 1 or a pharmaceutically acceptable derivative thereof in a pharmaceutically acceptable carrier, wherein the amount is effective for ameliorating the symptoms of an endothelin-mediated disease. 26. A pharmaceutical composition, comprising an effective amount of a compound of claim 11 or a pharmaceutically acceptable derivative thereof in a pharmaceutically acceptable carrier, wherein the amount is effective for ameliorating the symptoms of an endothelin-mediated disease. 27. The composition of claim 25 that is formulated for single or multiple dosage administration. 28. The composition of claim 26 that is formulated for single or multiple dosage administration. 29. An article of manufacture, comprising packaging material and a compound or a pharmaceutically acceptable derivative thereof of claim 1 contained within the packaging material, wherein the compound is effective for antagonizing the effects of endothelin, ameliorating the symptoms of an endothelin-mediated disorder, or inhibiting the binding of an endothelin peptide to an ET receptor with an IC.sub.50 of less than about 10 .mu.M, and the packaging material includes a label that indicates that the sulfonamide or derivative thereof is used for antagonizing the effects of endothelin, inhibiting the binding of endothelin to an endothelin receptor or treating an endothelin-mediated disorder. 30. An article of manufacture, comprising packaging material and a compound or a pharmaceutically acceptable derivative thereof of claim 11 contained within the packaging material, wherein the compound is effective for antagonizing the effects of endothelin, ameliorating the symptoms of an endothelin-mediated disorder, or inhibiting the binding of an endothelin peptide to an ET receptor with an IC.sub.50 of less than about 10 .mu.M, and the packaging material includes a label that indicates that the sulfonamide or derivative thereof is used for antagonizing the effects of endothelin, inhibiting the binding of endothelin to an endothelin receptor or treating an endothelin-mediated disorder. 31. A method for the treatment of endothelin-mediated diseases, comprising administering to a subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable derivative thereof, wherein the effective amount is sufficient to ameliorate one or more of the symptoms of the disease. 32. A method for the treatment of endothelin-mediated diseases, comprising administering to a subject an effective amount of a compound of claim 11, or a pharmaceutically acceptable derivative thereof, wherein the effective amount is sufficient to ameliorate one or more of the symptoms of the disease. 33. The method of claim 31, wherein the disease is selected from the group consisting of hypertension, cardiovascular diseases, cardiac diseases including myocardial infarction, pulmonary hypertension, neonatal pulmonary hypertension, erythropoietin-mediated hypertension, respiratory diseases and inflammatory diseases, including asthma, bronchoconstriction, ophthalmologic diseases including glaucoma and inadequate retinal perfusion, gastroenteric diseases, renal failure, endotoxic shock, menstrual disorders, obstetric conditions, wounds, laminitis, erectile dysfunction, menopause, osteoporosis and metabolic bone disorders, climacteric disorders including hot flushes, abnormal clotting patterns, urogenital discomfort, increased incidence of cardiovascular disease and other disorders associated with the reduction in ovarian function in middle-aged women, pre-eclampsia, control and management of labor during pregnancy, nitric oxide attenuated disorders, anaphylactic shock, hemorrhagic shock and immunosuppressant-mediated renal vasoconstriction. 34. The method of claim 32, wherein the disease is selected from the group consisting of hypertension, cardiovascular diseases, cardiac diseases including myocardial infarction, pulmonary hypertension, neonatal pulmonary hypertension, erythropoietin-mediated hypertension, respiratory diseases and inflammatory diseases, including asthma, bronchoconstriction, ophthalmologic diseases including glaucoma and inadequate retinal perfusion, gastroenteric diseases, renal failure, endotoxic shock, menstrual disorders, obstetric conditions, wounds, laminitis, erectile dysfunction, menopause, osteoporosis and metabolic bone disorders, climacteric disorders including hot flushes, abnormal clotting patterns, urogenital discomfort, increased incidence of cardiovascular disease and other disorders associated with the reduction in ovarian function in middle-aged women, pre-eclampsia, control and management of labor during pregnancy, nitric oxide attenuated disorders, anaphylactic shock, hemorrhagic shock and immunosuppressant-mediated renal vasoconstriction. 35. The method of claim 33, wherein the disease is selected from the group consisting of asthma and inflammatory diseases. 36. The method of claim 33, wherein the disease is glaucoma. 37. The method of claim 34, wherein the disease is selected from the group consisting of asthma and inflammatory diseases. 38. The method of claim 34, wherein the disease is glaucoma. 39. A method for inhibiting the binding of an endothelin peptide to an endothelin.sub.A (ET.sub.A) or endothelin.sub.B (ET.sub.B) receptor, comprising contacting the receptor with a compound of claim 1, or a pharmaceutically acceptable derivative thereof, wherein: the contacting is effected prior to, simultaneously with or subsequent to contacting the receptor with the endothelin peptide. 40. A method for inhibiting the binding of an endothelin peptide to an endothelin.sub.A (ET.sub.A) or endothelin.sub.B (ET.sub.B) receptor, comprising contacting the receptor with a compound of claim 11, or a pharmaceutially acceptable derivative thereof, wherein: the contacting is effected prior to, simultaneously with or subsequent to contacting the receptor with the endothelin peptide. 41. A method for altering endothelin receptor-mediated activity, comprising contacting an endothelin receptor with a compound of claim 1, or a pharmaceutically acceptable derivative thereof. 42. A method for altering endothelin receptor-mediated activity, comprising contacting an endothelin receptor with a compound of claim 11, or a pharmaceutically acceptable derivative thereof. 43. The pharmaceutical composition of claim 25, wherein the pharmaceutically acceptable carrier comprises a sodium phosphate buffer solution containing a sugar. 44. The pharmaceutical formulation of claim 43, wherein the compound is a pharmaceutically-acceptable alkali metal salt. 45. A lyophilized powder, comprising a salt of the compound of claim 1. 46. The lyophilized powder of claim 45 produced by a process, comprising: (a) dissolving a pharmaceutically-acceptable salt of the sulfonamide compound in a sodium phosphate buffer solution containing a sugar or carbohydrate; (b) sterile-filtering the resulting solution; and (c) lyophilizing the filtered solution under standard conditions to produce a sterile powder. 47. The powder of claim 46, wherein the sugar or carbohydrate contains dextrose. 48. An article of manufacture, comprising packaging material and the powder of claim 45, contained within the packaging material, wherein the compound is effective for antagonizing the effects of endothelin, ameliorating the symptoms of an endothelin-mediated disorder, or inhibiting the binding of an endothelin peptide to an ET receptor with an IC.sub.50 of less than about 1 .mu.M, and the packaging material includes a label that indicates that the sulfonamide or salt thereof is used for antagonizing the effects of endothelin, inhibiting the binding of endothelin to an endothelin receptor or treating an endothelin-mediated disorder. 49. A combination comprising: a sterile vial containing the pharmaceutical formulation of claim 45. 50. The combination of claim 49, wherein the sterile vial contains an amount of the powder that is for single dose administration. 51. The combination of claim 49, wherein the sterile vial also contains an amount of sterile water for injection; and the final concentration of the sulfonamide sodium salt is between about 1 and 250 mg/mL. 52. The pharmaceutical composition of claim 25 that is formulated as a tablet or capsule. 53. The composition of claim 52, further comprising an enteric coating. 54. The composition of claim 53, wherein the coating is selected from cellulose acetate phthalate, polyethylene glycol, polyoxyethylene sorbitan, castor oil, ethyl cellulose pseudolatex, phenyl salicylate, n-butyl stearate, stearic acid and carnuba wax. 55. The pharmaceutical composition of claim 26, wherein the pharmaceutically acceptable carrier comprises a sodium phosphate buffer solution containing a sugar. 56. The pharmaceutical formulation of claim 55, wherein the compound is a pharmaceutically-acceptable alkali metal salt. 57. A lyophilized powder, comprising a salt of the compound of claim 11. 58. The lyophilized powder of claim 57 produced by a process, comprising: (a) dissolving a pharmaceutically-acceptable salt of the sulfonamide compound in a sodium phosphate buffer solution containing a sugar or carbohydrate; (b) sterile-filtering the resulting solution; and (c) lyophilizing the filtered solution under standard conditions to produce a sterile powder. 59. The powder of claim 58, wherein the sugar or carbohydrate contains dextrose. 60. An article of manufacture, comprising packaging material and the powder of claim 57, contained within the packaging material, wherein the compound is effective for antagonizing the effects of endothelin, ameliorating the symptoms of an endothelin-mediated disorder, or inhibiting the binding of an endothelin peptide to an ET receptor with an IC.sub.50 of less than about 1 .mu.M, and the packaging material includes a label that indicates that the sulfonamide or salt thereof is used for antagonizing the effects of endothelin, inhibiting the binding of endothelin to an endothelin receptor or treating an endothelin-mediated disorder. 61. A combination comprising: a sterile vial containing the pharmaceutical formulation of claim 57. 62. The combination of claim 61, wherein the sterile vial contains an amount of the powder that is for single dose administration. 63. The combination of claim 61, wherein the sterile vial also contains an amount of sterile water for injection; and the final concentration of the sulfonamide sodium salt is between about 1 and 250 mg/mL. 64. The pharmaceutical composition of claim 26 that is formulated as a tablet or capsule. 65. The composition of claim 64, further comprising an enteric coating. 66. The composition of claim 65, wherein the coating is selected from cellulose acetate phthalate, polyethylene glycol, polyoxyethylene sorbitan, castor oil, ethyl cellulose pseudolatex, phenyl salicylate, n-butyl stearate, stearic acid and carnuba wax. 67. A pharmaceutical composition, comprising an effective amount of a compound of claim 19 or a pharmaceutically acceptable derivative thereof in a pharmaceutically acceptable carrier, wherein the amount is effective for ameliorating the symptoms of an endothelin-mediated disease. 68. The composition of claim 67 that is formulated for single or multiple dosage administration. 69. An article of manufacture, comprising packaging material and a compound or a pharmaceutically acceptable derivative thereof of claim 19 contained within the packaging material, wherein the compound is effective for antagonizing the effects of endothelin, ameliorating the symptoms of an endothelin-mediated disorder, or inhibiting the binding of an endothelin peptide to an ET receptor with an IC.sub.50 of less than about 10 .mu.M, and the packaging material includes a label that indicates that the sulfonamide or derivative thereof is used for antagonizing the effects of endothelin, inhibiting the binding of endothelin to an endothelin receptor or treating an endothelin-mediated disorder. 70. A method for the treatment of endothelin-mediated diseases, comprising administering to a subject an effective amount of a compound of claim 19, or a pharmaceutically acceptable derivative thereof, wherein the effective amount is sufficient to ameliorate one or more of the symptoms of the disease. 71. The method of claim 70, wherein the disease is selected from the group consisting of hypertension, cardiovascular diseases, cardiac diseases including myocardial infarction, pulmonary hypertension, neonatal pulmonary hypertension, erythropoietin-mediated hypertension, respiratory diseases and inflammatory diseases, including asthma, bronchoconstriction, ophthalmologic diseases including glaucoma and inadequate retinal perfusion, gastroenteric diseases, renal failure, endotoxic shock, menstrual disorders, obstetric conditions, wounds, laminitis, erectile dysfunction, menopause, osteoporosis and metabolic bone disorders, climacteric disorders including hot flushes, abnormal clotting patterns, urogenital discomfort, increased incidence of cardiovascular disease and other disorders associated with the reduction in ovarian function in middle-aged women, pre-eclampsia, control and management of labor during pregnancy, nitric oxide attenuated disorders, anaphylactic shock, hemorrhagic shock and immunosuppressant-mediated renal vasoconstriction. 72. The method of claim 71, wherein the disease is selected from the group consisting of asthma and inflammatory diseases. 73. The method of claim 71, wherein the disease is glaucoma. 74. A method for inhibiting the binding of an endothelin peptide to an endothelin.sub.A (ET.sub.A) or endothelin.sub.B (ET.sub.B) receptor, comprising contacting the receptor with a compound of claim 19, or a pharmaceutically acceptable derivative thereof, wherein: the contacting is effected prior to, simultaneously with or subsequent to contacting the receptor with the endothelin peptide. 75. A method for altering endothelin receptor-mediated activity, comprising contacting an endothelin receptor with a compound of claim 19, or a pharmaceutially acceptable derivative thereof. 76. The pharmaceutical composition of claim 67, wherein the pharmaceutically acceptable carrier comprises a sodium phosphate buffer solution containing a sugar. 77. The pharmaceutical formulation of claim 76, wherein the compound is a pharmaceutically-acceptable alkali metal salt. 78. A lyophilized powder, comprising a salt of the compound of claim 19. 79. The lyophilized powder of claim 78 produced by a process, comprising: (a) dissolving a pharmaceutically-acceptable salt of the sulfonamide compound in a sodium phosphate buffer solution containing a sugar or carbohydrate; (b) sterile-filtering the resulting solution; and (c) lyophilizing the filtered solution under standard conditions to produce a sterile powder. 80. The powder of claim 79, wherein the sugar or carobohydrate contains dextrose. 81. An article of manufacture, comprising packaging material and the powder of claim 78, contained within the packaging material, wherein the compound is effective for antagonizing the effects of endothelin, ameliorating the symptoms of an endothelin-mediated disorder, or inhibiting the binding of an endothelin peptide to an ET receptor with an IC.sub.50 of less than about 1 .mu.M, and the packaging material includes a label that indicates that the sulfonamide or salt thereof is used for antagonizing the effects of endothelin, inhibiting the binding of endothelin to an endothelin receptor or treating an endothelin-mediated disorder. 82. A combination comprising: a sterile vial containing the pharmaceutical formulation of claim 78. 83. The combination of claim 82, wherein the sterile vial contains an amount of the powder that is for single dose administration. 84. The combination of claim 82, wherein the sterile vial also contains an amount of sterile water for injection; and the final concentration of the sulfonamide sodium salt is between about 1 and 250 mg/mL. 85. The pharmaceutical composition of claim 67 that is formulated as a tablet or capsule. 86. The composition of claim 85, further comprising an enteric coating. 87. The composition of claim 86, wherein the coating is selected from cellulose acetate phthalate, polyethylene glycol, polyoxyethylene sorbitan, castor oil, ethyl cellulose pseudolatex, phenyl salicylate, n-butyl stearate, stearic acid and carnuba wax.

Details for Patent 6,686,382

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2019-12-31